Daniel Paul Regan is Chief Commercial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT). They have made 1 open-market trade across 1 company since 2014, most recently 2018-12-12.
CIK 0001571320
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ICPT | SELL · 10b5-1 | 2015-01-30 | 2015-02-03 | $201.07 | $2.0M | -17.1% | +1.2% | +1.2% |
| ICPT | SELL | 2015-01-05 | 2015-01-07 | $176.49 | $26K | -17.1% | +1.2% | +1.2% |
| ICPT | SELL · 10b5-1 | 2014-08-12 | 2014-08-15 | $325.70 | $2.6M | -17.1% | +1.2% | +1.2% |
| ICPT | SELL · 10b5-1 | 2014-07-03 | 2014-07-08 | $250.00 | $250 | -17.1% | +1.2% | +1.2% |
| ICPT | SELL · 10b5-1 | 2014-03-05 | 2014-03-07 | $434.69 | $8.7M | -17.1% | +1.2% | +1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.